Last Update: Thursday, February 1, 2007. 1:27pm (AEDT)
Indonesia critical of Aust company's bird flu vaccine development
By Geoff Thompson
The Indonesian Government says Australian company CSL should have sought its permission to develop a bird flu vaccine using the Indonesian strain of the H5N1 virus.
The death told from bird flu in Indonesia stands at 62 and authorities are preparing to enforce strict controls on people raising poultry.
Sweeps begin across Jakarta today to capture and kill any backyard birds not already handed over to authorities.
But news this week that the Australian pharmaceuticals company CSL had developed a vaccine against the H5N1 bird flu virus was met with alarm by Indonesian Health Minister Siti Fadillah Supari.
She says Indonesia is seeking intellectual property rights over the Indonesian strain of the virus on which the vaccine is based.
But CSL spokeswoman, Dr Rachel David, says it is not possible to "own" strains of bird flu.
Dr David says the company received its stock of the virus from the World Health Organisation (WHO).
"To talk about strains of the flu as being something you can own is no a useful concept - it's like trying to grasp smoke," she said.
"It's not a useful concept in dealing with this disease."
Dr David also says the vaccine is not being developed for commercial purposes.
"If, and only if, a pandemic flu was to become a problem, that particular amount of money in that contract is fixed," she said.
"It's not something we can profiteer out of and in fact it's not something that we see as being a commercial exercise at all."
CSL says it will not comment further because the issue is between the World Health Organisation, the Australian Government and the Indonesian Government.
- Forums
- ASX - By Stock
- CSL
- this got to be a joke
this got to be a joke
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
Add CSL (ASX) to my watchlist
(20min delay)
|
|||||
Last
$288.93 |
Change
0.320(0.11%) |
Mkt cap ! $139.9B |
Open | High | Low | Value | Volume |
$287.64 | $289.70 | $287.16 | $174.5M | 601.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 149 | $288.79 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$288.96 | 1858 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2 | 288.780 |
1 | 1 | 288.700 |
1 | 1297 | 288.580 |
1 | 1297 | 288.430 |
1 | 651 | 288.340 |
Price($) | Vol. | No. |
---|---|---|
288.960 | 1858 | 1 |
289.000 | 1006 | 2 |
289.070 | 850 | 1 |
289.130 | 297 | 1 |
289.220 | 894 | 1 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |